MASLD/MASH: Clinical and Economic Findings from 40-year Follow-Up Data

Dec 2024

The chronic nature of metabolic dysfunction-associated steatotic liver disease necessitates a comprehensive understanding of the factors driving long-term clinical outcomes, as well as the associated high costs and healthcare resource utilization. This understanding is crucial for raising disease awareness, early identification of at-risk patients, timely initiation of treatment to prevent disease progression, and ultimately minimizing both clinical and economic burdens. In this webinar, experts will report the findings of the BRIDGE-MASH study, assessing clinical and economic outcomes in a cohort of patients with an unprecedented follow-up period of more than 40 years.

Leveraging the Value of Clinical Outcomes in DMD for Decision Making

Dec 2024

Rare diseases often face challenges in appropriate clinical trial design that offers a patient-centric approach, such as issues with the selection of endpoints; adequate size population samples; variations in control groups. Duchenne Muscular Dystrophy (DMD) is a rare and fatal genetic neuromuscular disorder that is caused by mutations in a gene located on the X chromosome. In this webinar, a clinician, patient/caregiver, and an industry representative will review how DMD clinical trials are designed, the endpoints most often used, and their relevance to inform decision making.

The Burden of Time: MS Treatment and Socio-Economic Impact Reduction

Oct 2024

The webinar will present a novel study that explores the impact of Multiple Sclerosis (MS) on patients’ health and overall well-being, highlighting the importance of early access to disease-modifying treatments (DMTs) with convenient administration.

IRA Part III: Medicare’s Maximum Fair Prices for the First 10 Negotiated Drugs and Anticipated Cost Savings

Oct 2024

Drs. Inma Hernandez and Sean D. Sullivan will compare the recently published Medicare Maximum Fair Prices (MFPs) with net prices before negotiation to discuss the potential magnitude of savings achieved by negotiation. Drs. John O’Brien of the National Pharmaceutical Council and Greg Daniel of Eli Lilly will provide additional context for the MFPs and the estimated cost savings projections. This session will be highly relevant for professionals and researchers in market access, pricing, and HEOR.

Evidence Generation for JCAs: How Can AI Boost Efficiency and Maintain Quality?

Oct 2024

This webinar will benefit stakeholders involved in health technology assessment (HTA), artificial intelligence (AI) development, and AI regulation by providing a comprehensive debate on the use of AI in Joint Clinical Assessments (JCAs).

Global Perspective on Inequality Aversion: Methods and Learnings

Oct 2024

Inequality aversion represents the degree of concern for reducing a specified inequality, which can also be interpreted as the value that a given stakeholder places on changes in health inequalities. Information on aversion to inequality is often expressed as inequality aversion parameters, such as the Atkinson index. Such parameters can be applied to forms of equity analysis, including distributional cost-effectiveness analysis (DCEA) that enables researchers to evaluate both the equity and effectiveness of healthcare interventions and the broader impacts of healthcare decisions. Incorporating inequality aversion parameters in DCEA facilitates the exploration of the consequences of different social value judgments when comparing policy options that involve trade-offs between improving total health and reducing health inequality.

Patient Involvement in Value and Health Technology Assessment (V/HTA)

Oct 2024

Patient involvement in HTA and broader value assessment is an essential aspect of promoting patient-centered decision-making in healthcare. Historically, patient involvement in these processes has been limited, leading to decisions that may not fully consider patient perspectives, preferences, and values. However, without offering any recognizable value to patients, health technologies may fail to generate value in the healthcare system. Therefore, the objective of this webinar is to emphasize the significance of patient involvement in HTA and broader value assessment and to delve into the challenges associated with it, while also presenting potential solutions.

Conducting Research and Survey Studies in Hard-to-Reach Populations

Oct 2024

The patient is at the center of survey, health preference, and patient-reported outcome (PRO) research. By their nature, hard-to-reach populations are difficult to engage in health research, as they may not be recruitable through commonly used channels or may need additional assistance with survey tasks or different modes of administration for PROs and preference tasks. With survey, preference and PRO research increasingly being conducted online due to time and budgetary efficiencies, the likelihood of successfully involving hard-to-reach populations becomes ever smaller. But when the research question concerns the hard-to-reach populations, how can we ensure that the results reflect their views?

Can GenAI for Literature Reviews Ever Be Trusted? A Pragmatic Approach That’s Ethically Designed and Purpose-built for HEOR Professionals

Oct 2024

This session will highlight practical use cases and best practices in applying AI to meet the demands of health technology assessments (HTA), health economics and outcomes research (HEOR) and surveillance activities.

Transferability of Data and Methods to Central and Eastern Europe

Sep 2024

The aim of this webinar is to discuss the questions: What are the main barriers which prevent transferring data and methods in CEE, originally generated in Western Europe? What are the proposed solutions to overcome these barriers and opportunities?

Moving Toward Universal Health Coverage in Africa: The Role of HTA

Aug 2024

Most African countries have integrated universal health coverage (UHC) as a goal in their national health strategies. To strengthen commitment and accelerate progress towards UHC, it is important for countries to effectively address challenges associated with expanded healthcare utilization. In this webinar, experts from the Africa region will discuss the role of HTA for advancing UHC and share lessons on how to structure health systems to implement HTA and how to use HTA to inform UHC decision-making.

The Role of RWE for Devices and Diagnostic Market Access in Europe

Jul 2024

To inform and guide this discussion, the speakers will present country-specific key decision pathways for MD&D reimbursement to compare and contrast evidence requirements and explore whether RWE can fulfill those needs. These elements will be accompanied by examples which will consider the impact of country related HTA hurdles, RWE definitions and the validation of RWE to make it acceptable for decision-making bodies. The debate will then focus on the strengths and limitations of real-world data in the context of reimbursement decision making; this will include the acceptance of RWE from other regions (eg., the US) in Europe, issues around the use/access of RWE in compliance with GDPR rules and the perspectives on RWE quality to ensure fit for purpose.

ISPOR Top 10 HEOR Trends - What Are the Key Themes for 2024-2025?

Jun 2024

Hear from ISPOR’s Chief Science Officers, who will begin with the methods underlying the report, and then will discuss each of the Top 10 topics, the HEOR considerations related to each one, and how ISPOR members are engaged in them, and will conclude with a question and answer period.

Overcoming the Barriers of Open-Source Modeling

Jun 2024

The development and use of Open-Source Models (OSM) promises to increase the transparency and efficiency of health economic modelling endeavors. However, the number of open-source health economic models remains low. A recent survey of the ISPOR OSM Special Interest Group identified several barriers and opportunities for the development of OSM. However, little has been discussed in the literature on which barriers to OSM are most relevant for different stakeholder groups and how different stakeholders would address these barriers. Therefore, this webinar attempts to address this knowledge gap by bringing together stakeholders from different professional backgrounds.

Assessing the Fiscal Burden of Obesity Using a Public Economic Framework

May 2024

Obesity is a health priority for many governments because of its impact on population health and its economic consequences. We aimed to measure the wider effects of obesity in Japan and Canada by using a government perspective framework that accounts for lost tax revenues and higher government spending on social benefit programs.

Are Clinical Outcome Assessments Sufficiently Valued?

May 2024

The aim of the webinar is to increase awareness of the challenges associated with generating PRO data and its value to different stakeholders and generate discussion to inform potential solutions to these challenges. Finally, the webinar will provide information about the content of the SISAQOL-IMI recommendations and how they can be used.

The Global Socioeconomic Impact of Rare Diseases: A Call for Action

May 2024

The webinar will begin with an introduction of the participants of the study to the ISPOR Rare Disease (RD) SIG, followed by an overview of the study objectives, its methodology and findings. The novel study explored the burden of different RDs across a range of countries, including low-and-middle-income countries (LMICs). The diseases and countries were chosen to allow for a diverse and relevant representation of RD burden globally, aiming to capture cross-disease and cross-country unmet needs, and consequent areas for policy intervention.

Revolutionizing Systematic Reviews: Harnessing the Power of AI

May 2024

This webinar will provide a comprehensive overview of the current landscape of AI adoption in systematic reviews and showcase several state-of-the-art platforms revolutionizing the systematic review process.

Revolutionizing Clinical Trials: Harnessing Real-World Evidence to Drive Diversity and Clinical Implementation

Apr 2024

In this session, we'll discuss leveraging RWE to enhance diversity within clinical trials and expedite the translation of research findings into real-world clinical practice. Our expert panel will illuminate how RWE can address existing disparities in clinical trial participation, amplify the voices of underrepresented communities, and ultimately lead to more effective and equitable healthcare interventions.

Measuring the Indirect Costs Driving Financial Toxicity in Oncology

Apr 2024

In this webinar, experts will characterize financial toxicity from the patient perspective, suggest potential frameworks for incorporation of financial toxicity into economic evaluation, and discuss areas where further research is necessary.

Beyond the Boundaries of RCT Data: Connecting Trials to the Real-World

Apr 2024

Join Inovalon’s experts as they discuss the power of combining RCT with real-world data, through innovative data-linking techniques, to transform understanding of the patient journey to uncover invaluable insights into clinical and economic outcomes in the real-world.

Measuring Value in Oncology: Are We Keeping Pace with Science?

Mar 2024

This panel will discuss different perspectives on the utilization of these principles to advance value frameworks that help timely access to transformative treatments for people with cancer.

Patient WAIT Survey Findings Across 8 LATAM Countries

Feb 2024

During the webinar the speakers will present the FIFARMA W.A.I.T. indicator, which assesses the availability of innovative medicines for oncology and orphan diseases in 8 Latin American countries: Peru, Colombia, Chile, Mexico, Brazil, Costa Rica, Argentina, and Ecuador.

Digital Technologies for Health Systems: The African Experience

Dec 2023

This webinar focuses on important developments within the African continent. The main learning objectives are (1) to outline country experiences on rolling out digital health technologies, (2) discuss the role of big data analytics, and (3) describe the future prospects in the African context.

Tokenization in Clinical Trials: Benefits and End-to-End Enablement

Dec 2023

This webinar will provide a brief background on tokenization and its benefits. It will focus on end-to-end considerations for tokenizing data of clinical trial participants and designing fit for purpose studies based on linked real-world datasets.

ISPOR Professional Competencies for HEOR Professionals

Nov 2023

The ISPOR HEOR Competencies Framework, originally published in 2020, provides a set of competencies to serve as a guide on the knowledge, attitudes, and behaviors needed to perform effectively in the HEOR discipline. As the HEOR field advances, so do the job types and the breadth of topics in which professionals must demonstrate competence.

Payer Views on Prescription Digital Therapeutics in the US and Canada

Oct 2023

The purpose of this webinar is to address this topic from the patients' perspective, outline how patients can be involved in the development and implementation of digital health initiatives and the impact and value for the patient community, including more ethical, faster, effective, and appropriate outcomes.

How Does Biosimilar Availability Create Value for the Patient? A Conversation About Avenues to Widen Access to Biologics

Oct 2023

The aim of this webinar is to discuss real-life examples on how biosimilar adoption has positively impacted care and patient access to biological therapies, focusing on testimonies from patient, policy, and healthcare professional representatives. Speakers are invited to converse on what the tangible benefits are that biosimilars have delivered for patients, and how biosimilar availability has supported access to care and the implementation of optimized disease management initiatives.

External Control Arms - Application, Key Methods, and Acceptability

Oct 2023

This webinar will address when and why external control arms (ECA) are used, the acceptable types of data and methods to build ECAs, and circumstances under which ECAs are accepted from regulatory and HTA bodies.

Applications of Large Language Models for RWD Analytics

Oct 2023

In this webinar, we will give an overview of LLMs and share practical advice and cutting-edge examples about how to use them to help carry out real-world evidence (RWE) studies. We will also show how integrating GPT into population health analytics enables complex real-world datasets to be explored using simple language queries to transform the way that decision makers use data to identify unmet health needs.

Harnessing Horses and Zebras in Predictive Analytics: Methodological Considerations for Extreme Population Sizes in Real-World Evidence Generation

Sep 2023

This webinar is aimed at those who perform or use the results of real-world evidence (RWE) studies. It aims to describe the use of predictive analytics and machine learning for causal inference in the context of the extremes for disease populations: rare diseases and common conditions such as obesity.

How to Drive Value in the Digital Transformation Era?

Sep 2023

The multi-stakeholder panel in this webinar will discuss how to strike the balance between openness and security in the process of health data collection for the successful value assessment regarding digital solutions.

Application of Distributional Cost-Effectiveness Analysis to the US Setting

Sep 2023

This webinar will provide an educational opportunity for the ISPOR membership to learn about how distributional cost-effectiveness analysis (DCEA) can be applied in the US setting. This webinar will introduce the method, discuss the current state of foundational data in the US and highlight a recent case study to illustrate data sources that can be leveraged in more routine DCEA application.

Innovative Uses of Technology to Advance Health Preference Research

Sep 2023

Stated preference surveys often involve communicating large volumes of complex and/or unfamiliar medical information to provide context for respondents. This webinar examines innovative uses of technology to advance discrete choice experiment (DCE) research within health preference research. They will explore the different technologies that can be integrated into preference surveys illustrating how technology can better inform and potentially engage respondents.

The Use of Real-World Evidence in HTA in Central and Eastern Europe

Sep 2023

This webinar will cover the opportunities and challenges of collecting real-world data (RWD) and generating real-world evidence (RWE) for making better decisions in healthcare, specifically in Health Technology Assessment (HTA).

Communicating High Value in Scientific Publications

Sep 2023

This webinar will introduce several strategies for communicating the results of your study. These strategies can be used regardless of study methodology (eg, chart reviews, database analyses, economic models) and publication type (eg, abstract, poster, manuscript, report). As the field of HEOR continues to proliferate, the need for timely, clear, concise publications has never been greater.

Driving Health Outcomes: Exploring Value-Based Procurement

Aug 2023

Value-Based Procurement (VBP) is a critical element of a value-based healthcare system, offering a transformative purchase approach that addresses underlying barriers to access to innovative treatments. Unlike the traditional procurement methods that focus primarily on cost containment, VBP considers multiple factors, including the unique circumstances of each country, such as local disease burden, health priorities, infrastructure, supply chain, ability to pay for healthcare, and budget processes.

Health is Wealth

Jul 2023

This webinar will inaugurate the third edition of the series of webinars sponsored by FIFARMA on Value and Access to Innovation, and will be focused on exploring the relationship between health and the economy and how to ensure the long term healthcare system sustainability.

Economic Evaluation of Digital Health Technologies

Jul 2023

This webinar aims to provide insights into the economic evaluation of digital health technology, which presents unique challenges compared to pharmaceuticals, healthcare services, and medical devices. In this webinar, you will learn about the current role of health economics and outcomes research in assessing the value of digital health technologies, as well as the impact of digital health interventions in today’s healthcare systems.

Assessing Causal Treatment Effect for Sequenced Oncology Regimens

Jul 2023

In oncology, sequential use of treatments with different mechanisms of action is common practice to overcome cross-resistance . Over the past decade, treatment sequencing with novel immunotherapy and targeted agents has contributed to substantial improvement in clinical outcomes in cancer patients. However, such clinical practice introduces methodology challenges for HTA.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 3

Jul 2023

With the public comment period open until July 2023, this webinar will also present ISPOR members with the opportunity to ask questions and provide comments that will help inform ISPOR’s response on the draft guidance 4 document.

Assessment of Digital Health Technologies in the Asia Pacific Region

Jun 2023

This webinar is based off discussions that were held at the 2023 ISPOR HTA Roundtable – Asia Pacific on 8 March 2023. The HTA Roundtable focused on how countries or jurisdictions in the Asia Pacific region are assessing digital health technologies. This webinar will provide perspectives from different stakeholders and jurisdictions on the status of digital health assessments in the region.

Challenges in Rare Disease Diagnostics: An Overview

Jun 2023

This webinar is aimed at all those who undertake research and development as well as value assessment of therapies and diagnostics in the rare disease space. It aims to expose the “diagnostic odyssey” and explain why a definitive diagnosis is not only important for patients but also for those assessing value. Objectives are to 1) explain what can be done to improve diagnosis in rare diseases and 2) why it matters in the context of value assessment.

Clinical Trial Innovation: How Healthcare Technology is Evolving

Jun 2023

Join us as we discuss how the healthcare landscape is changing in technology and clinical trial innovation, including diversity improvement, leveraging real-world evidence, comparative arms, and decentralized clinical trials.

Introduction to Open-Source Modeling: R We There Yet?

Apr 2023

In this forum, the OSM Special Interest Group has selected leaders in the field of health economics to describe their approach to OSMs. Mohsen Sadatsafavi will introduce the Peer Models Network and PRISM service as part of "Open-access modelling as a companion to open-source modelling” illustrated with an example implemented for Chronic Obstructive Pulmonary Disease (the Evaluation Platform in COPD (EPIC) model.)

Health Equity in HEOR: Past, Present & Future Research Implications

Apr 2023

The webinar will provide an overview of past and current efforts in health equity, its role in health outcomes research, and its future implications in the field.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 2

Mar 2023

In this webinar series, we will hear from patient representatives and FDA staff to learn what is covered in this guidance series and what these new guidances mean for patient-focused drug development and the HEOR community.

Improving Treatment Access and Outcomes by Integrating Social Determinants of Health Data With Real-World Evidence

Feb 2023

This webinar will focus on how integrating social determinants of health (SDOH) data with claims-based research can provide an opportunity to improve treatment access and outcomes for under-represented populations through targeted research and strategic efforts.

Preventing, Detecting, and Analyzing Data From Suspected Fraudulent Respondents in Online Surveys, with Examples From Health Preference Studies

Feb 2023

The workshop will use real-time polling to understand the audience’s experiences with data collection fraud online and the methods used to prevent and identify data collection fraud. We will encourage audience members to share their own strategies, learnings, and challenges.

Digital Endpoint Adoption: the How, What and Why

Feb 2023

Focusing on clinical neurosciences (CNS), and using first-hand experience from a Parkinson’s study, experts from Parexel discuss how to integrate eCOA science and sensor technology into clinical trials.

FDA Patient-Focused Drug Development (PFDD) Guidance - Part 1

Feb 2023

This is part one of a two-part webinar series. The FDA is developing Patient-Focused Drug Development (PFDD) guidance to inform the inclusion of patient experience when developing new medical therapies and products. This is a four-part guidance series, with two final guidances released, a third draft guidance released and a fourth guidance under development.

Achieving Fit for Purpose Data from Wearables for Age-Related Diseases

Jan 2023

An ageing population means an urgent need for better and effective treatment for age-related illnesses. Despite billion-dollar investments for drug development for these conditions, especially neurogenerative diseases, there is a low success rate and it is a slow process.

Strategies and Skills to Land Your First Job: The Interview

Dec 2022

The ISPOR Student Network is pleased to present this three-part webinar series as a guide for landing their first job out of school.

Looking Beyond Survival Data: Understanding the Value of Non-OS Endpoints in Oncology Reimbursement Decision-Making

Dec 2022

In this webinar, representatives from different stakeholder groups (patients, physicians, health economists and industry) will discuss the value of increasing the use of non-OS endpoints in reimbursement decision-making to their stakeholder groups. Using the example of multiple myeloma, the speakers will discuss how and when non-OS endpoints should be used, to support a future in which assessments of novel therapies are more fit-for-purpose.

Different HTA Perspectives on Reliably Estimating Treatment Effects

Nov 2022

Real-World evidence (RWE) has recently received increased attention to provide supplementary evidence to support health technology assessment (HTA) submissions, especially as another source of insight into the real-world performance of novel therapeutic products, particularly when traditional randomized controlled trials (RCTs) are impractical or lack generalizability.

Actualización de Política de Salud: ISPOR América Latina

Nov 2022

Organizado por el Consorcio de ISPOR América Latina, esta reunión virtual presentó actualizaciones de políticas de salud y economía de la salud (HEOR) y conto con la participación de reconocidos expertos en la región.

Can the Benefits From Biosimilars Be Sustainably Increased? Policy Recommendations for Europe, Middle East and Canada

Oct 2022

Biosimilars offer great potential for the patients, payers and the whole society. However, there exist policy barriers which can hinder this potential. The debate will analyze the challenges and opportunities for biosimilars uptake in Europe, Middle East and Canada.

Oportunidades de carrera en HEOR para América Latina | Career Opportunities in HEOR in Latin America

Oct 2022

Hacemos una cordial invitación a los estudiantes, nuevos profesionales, y todos aquello interesado en discutir las oportunidades de desarrollo profesional que ofrece el campo de la Economía de la Salud e Investigación de Resultados (HEOR) en América Latina. Esta mesa redonde ofrecerá la perspectiva de diferentes sectores como la industria, el gobierno, la academia y la Evaluación de Tecnologías de la Salud (HTA) considerando las experiencias de distintos países en la región.

Health Insurance in Africa: Sustainability in Focus

Oct 2022

Many health systems in Africa are generally characterized by high burden of out-of-pocket payment by patients at the point of care and increased exposure of clients to catastrophic health payments. However, there are recent moves by many African countries to improve their health financing systems and institute health insurance in a bid to ensure universal health coverage.

Availability and Access to Innovative Therapies in Latin America

Oct 2022

This webinar will focus on discussing how to ensure access for the right patient, to the right treatment, at the right time. We invited Max Newton, Engagement Manager at IQVIA as guest speaker. Max worked on the development of the FIFARMA "Patients Waiting to Access Innovative Therapies (WAIT) Indicator survey"; he also is leading a similar survey in Europe, the "EFPIA WAIT indicator".

Souring On SUCRAs: When Treatment Ranking Goes Wrong

Oct 2022

This webinar will explore what the SUCRA is, demonstrate how it can be meaningfully impacted by network composition (even in simple networks), and suggest corrections to common errors in the reporting of SUCRAs.

On the Validity of Statistical Analyses with Privacy-Preserving Synthetic Data

Sep 2022

This webinar presents a brief tutorial on synthetic data generation, an overview of its privacy preserving properties, and then review the results from studies evaluating the validity of analyses using synthetic data.

Fit for Local Context? Establishing or Improving Deliberative Processes for HTA

Sep 2022

Deliberative processes for health technology assessment (HTA) are intended to facilitate participatory decision making, using discussion and open dialogue between stakeholders. Increasing attention is being given to deliberative processes, but guidance is lacking for those who wish to design or use them. Health Technology Assessment International (HTAi) and ISPOR initiated a joint task force that developed comprehensive guidance to address this gap. This webinar will be of benefit to all those involved in establishing or improving deliberative processes for HTA in local contexts.

Network Meta-Analysis - Special Topics

Sep 2022

The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first one is an introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna. The second webinar will feature more advanced content than the first webinar.

Clinical Outcome Assessments in the Asia Pacific Region: Strategy & Implementation

Sep 2022

Asia Pacific regional markets, including but not limited to mainland China, Japan, South Korea and Taiwan, play increasingly important roles in global clinical development. Patient-centric endpoints via clinical outcome assessments (COAs) and electronic COAs (eCOAs), are getting more and more attention in clinical research design and execution.

How Can Society Sustainably Benefit From Biosimilars? Global Learnings and Policy Recommendations for Australia

Sep 2022

This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society. There will be a specific focus on the issues in Australia and comparing those against examples found globally. Implications for patients, society as well as a discussion of the learnings in terms of policy provisions and best practices that can help solving these issues will also be held.

An Introduction to Network Meta-Analysis

Sep 2022

The Statistical Methods in Health Economics and Outcome Research Special Interest Group is pleased to present two webinars on Network Meta-Analysis (NMA). The first of two webinars will focus on the terms associated with network meta-analyses, how and why different comparisons are used, and the concepts, assumptions, and limitations associated with NMA. The first webinar is focused on an Introduction to NMA by Emma Hawe. The second will cover special topics in NMA by Sofia Dias. Both webinars will be moderated by Gian Luca Di Tanna.

Differentiating Between Patient Preferences, Patient Reported Outcomes and Patient Engagement

Sep 2022

The webinar will define patient preferences, patient-reported outcomes and patient engagement, by describing their core defining features, how they differ from one another, and outlining the complementary roles that they may have in understanding what matters to patients. The speakers will then discuss how patient preferences, patient-reported outcomes and patient engagement can play a role in marketing authorization and health technology assessment, and ultimately, facilitate better care and access to care for patients.

ISPOR Asia Pacific Region Student Webinar: Health Technology Assessment and Market Access

Aug 2022

This webinar intends to provide an overview of Health Technology Assessment and current developments in Indian market. The webinar will help participants learn different aspects of HTA.

Stakeholder Engagement in Value Assessment

Aug 2022

This is the Second webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams: (1) Funding: what is the relation between health & the economy and how to ensure the long term healthcare system sustainability, (2) Value: what are the value frameworks used by decision makers in LatAm and what is the impact on patient access, (3) Adoption: how to ensure access for the right patient, to the right treatment, at the right time.

Data Privacy and Digital Health: The Manufacturers/Payers Perspective

Jul 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

Financing Sustainable Healthcare Systems in Latin America

Jul 2022

This is the first webinar of the Value and Access to Innovation webseries sponsored by FIFARMA. The series are structured around FIFARMA's VAI working group workstreams.

Distributional Cost-Effectiveness Analysis to Inform Healthcare Decisions

Jun 2022

This webinar will aim to provide an educational opportunity for the ISPOR membership to learn about the methods for conducting distributional cost-effectiveness analysis (DCEA).

Oncology Endpoints in Reimbursement Decision-Making: Are We Keeping Pace With the Science?

Jun 2022

For cancer drugs, payers often prefer to make decisions based on overall survival (OS) outcomes. However, it may take many years to collect OS data; this is particularly apparent in early-stage cancer and when an active therapy is highly effective at extending life.

Sustainable Access to Biosimilars in the USA and Latin America: Challenges and Potential Solutions

Jun 2022

This webinar leverages recent global research conducted across 17 countries to provide an overview of the challenges and solutions to ensure the biosimilar benefits are sustainably delivered to the whole society.

The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model

May 2022

Real-world evidence has advanced health research over the past two or three decades. The challenges of procuring sufficient, high-quality real-world data, of unlocking the knowledge contained in the data, and of sharing information without compromising patient privacy are ever-present.

Accelerating Patient Access to Next Generation Sequencing

May 2022

Next-generation sequencing (NGS) is the key to precision medicine in oncology and delivers several benefits across the patient care pathway, from providing patients with a tailored therapeutic strategy, increasing efficiency in healthcare systems delivery of care, resulting in potential cost savings and benefits to future patients.

Value-Based Payment in Asia Pacific: Case Studies and Lessons Learned

Apr 2022

Health systems in Asia Pacific regions are under tremendous pressure to deal with the rising costs, unequal access to service, and uneven quality of care. More and more healthcare systems across the region have increasingly embraced a value-based health care (VBHC) agenda. How can we maximize value for money and optimize patient outcomes? How should healthcare be delivered and reimbursed? In light of these issues, this webinar brings together a panel of experts to discuss the current situation of value-based payment in the Asia Pacific region and beyond, challenges and opportunities for VBHC implementation in the region.

Student Network Fireside Chat: CHEERS 2022: Reporting Guidance for Health Economic Evaluation – Student Use and Application

Apr 2022

This fireside discussion led by the task force co-chairs will focus on the main changes from the original CHEERS and provide a quick live demonstration on how to use it.

ISPOR Top 10 HEOR Trends - What Are the Key Themes for 2022-23?

Apr 2022

ISPOR publishes the Top 10 HEOR Trends reports as part of its horizon scanning and monitoring of the trends that affect healthcare decision making around the world. ISPOR gathers information from its members on the current and future importance of a broad range of topics related to health, health care, health policy and scientific research.

Delivering Evidence-Based Access in Rare Diseases: The Challenges in SMA

Apr 2022

This session educates about the specific challenges of rare disease treatments in an HTA and discusses how Real-World Evidence Collection can address the data gap at the time of access decision.

Leveraging the Value of Clinical Outcome Assessment (COA) Data Beyond Labelling

Apr 2022

Speakers will discuss the many uses of COA data gathered during patient-focused drug development, including benefit/risk evaluation, HTA, access decisions, policy decisions, and clinician and patient decision-making.

Data Privacy as a Hurdle or Enabler for Digital Health Implementation? The Legal Framework

Apr 2022

The key success factor for digital health implementation is the information sharing across multiple stakeholders engaged in the clinical decision making. The COVID pandemic revealed numerous differences in how individual data are used in the process of the adoption of various digital health solutions in the healthcare systems across the globe.

HTA/Reimbursement Evolution and Priorities for Assessment in a Value-Based Healthcare Environment in Latin America

Mar 2022

This session will discuss trends in the HTA/Reimbursement environment in Latin America and the drivers for value-based health care (VBHC) implementation within the region. The potential benefits of VBHC, stakeholders’ roles in VBHC, contextual barriers and facilitators for VBHC implementation, and potential future impact of VBHC to healthcare in the region will be discussed by a panel of speakers.

Bariatric Surgery Reimbursement Seminar

Mar 2022

Experts from around the world will be sharing their experience about obesity treatment and reimbursement policies in their different countries. The event will consist of 7 expert presentations followed by a round table discussion with an opportunity for the audience to ask questions.

CHEERS 2022 - Reporting Guidance for Health Economic Evaluation: What It Is and How to Use It

Jan 2022

This webinar led by the task force co-chairs will focus on the main changes from the original CHEERS and a provide a quick live demonstration on how to use it. They will also discuss how a patient and public participation group was involved in the revision process, the resources being developed to support CHEERS 2022, the proposals for its dissemination and the involvement of a wide range of journals in the publication of the statement.

Improving Performance: Selection and Development of PerfO Assessments to Capture Clinical Benefit: Performance Outcome Assessment Emerging Good Practices Task Force

Jan 2022

This webinar will be useful for researchers, regulators, academics, industry sponsors, and instrument developers in the clinical outcomes assessment (COA) field working on the development, evaluation, and implementation of performance outcome (PerfO) measures for use in capturing clinical benefits in treatment trials for medical label claims.

Biosimilars' Key Next Steps: What Will the Future Bring?

Jan 2022

This webinar emerges in the sequence of relevant topics highlighted in the ISPOR Science Strategy (particularly the Special Populations and Technologies and Health Economics, Access and Policy sections) and the Special Interest Group on biosimilars, by specifically reflecting on how to tackle inefficiencies of healthcare systems in the future with biosimilars.

Health Preferences in HTA: Use of Patient and Public Preferences

Nov 2021

Consider payer decision making in the context of health preference research (HPR) in market access and health technology assessment (HTA). How does it fit together? What are the differences between patient preferences and public preferences as they apply to HTA? This webinar will provide a basic introduction to these issues and more.

Evolving Real World Data/Evidence Guidelines and Landscape in China: From Policy to Practice

Oct 2021

There is increasing demand for real-world evidence (RWE) in healthcare decision making around the global, same as in China. Being the world’s second-largest market (after the US) and the only major market growing in the high single-digits annually, the regulatory and market access environment is evolving rapidly amid the fast development of healthcare sector in China.

Health Preference Research in the Context of Gene Therapy in Rare Diseases

Sep 2021

During this webinar, the speakers will present their respective studies on gene therapy in Duchenne muscular dystrophy, spinal muscular atrophy (SMA) and hemophilia. They will discuss the importance of the disease context, the qualitative research that influenced attribute selection, the selection of health preference method and design of the health preferences’ tasks, and how the study findings relate to the potential value of gene therapy.

Embedded Clinical Trials: Understanding the Opportunities and Challenges for Real-World Evidence Generation

Sep 2021

In this webinar, experts will explore embedded clinical trials and their potential for effectively generating real world evidence, and review case studies illustrating best practice for these trials in action.

Innovations in Value Communication: Optimizing Payer Engagement at the Local Level

Sep 2021

Securing reimbursement from national payers is critical to your product’s commercial success. However, payers at the local and regional levels continue to get more authority to manage their own budgets. This makes engaging with payers and designing an effective strategy for value communication difficult as the concept of value can mean different things to different stakeholders.

The Health Preference Research Landscape - Preference Information, Methods, and Use

Aug 2021

This webinar is a collaboration between ISPOR’s Health Preference Research Special Interest Group and the New Professionals Network.

Use of External Controls for Oncology RWE Studies to Enhance Development and Accelerate Knowledge of New Treatments

Aug 2021

They will address challenges faced by the pharmaceutical industry with clinical trials and the potential benefits that may be addressed with external controls, including lower costs, increased efficiency, time savings and potential ways to introduce real-world data elements for regulatory decisions.

Current Healthcare Funding Models, Challenges and Opportunities in Middle East

Jul 2021

In this webinar, ISPOR Chapter members from the Arabic network will present the different funding channels in their countries, share experience about the current challenges and discuss possible opportunities that have not yet been explored.

ISPOR Educational Webinar: How to Improve Participatory Decision Making in HTA

Jul 2021

Panelists will discuss what approaches to use, describe the relevance for HTA organizations and how it might best be used, and will provide reflective thoughts on potential gaps, and where future efforts might be.

ISPOR Student Webinar: Health Economic Analyses and Modelling using R

Jul 2021

During this webinar Dr Petros Pechlivanoglou and Dr Koen Degeling will provide an overview and hands-on demonstration of the opportunities of using R software for health economic analyses and modelling.

Real World Oncology in China: Unique Opportunities to Drive Improved Patient Access and Outcomes

Jun 2021

The potential to improve cancer care in China is clear, the journey to that destination is not. Here, we bring together a group of experienced RWE leaders, thinkers, and “doers" for an interactive, friendly, and informative discussion about the unique attributes of oncology care in China: diverse patient journeys, integration with traditional medicines, immature EHR integration across institutions, and the rapidly evolving regulatory and reimbursement environment.

Implications of Matched Adjusted Indirect Treatment Comparisons in Rare Disease

Jun 2021

A one-hour educational webinar on the implications of matched adjusted indirect treatment comparisons in rare disease, using SMA as an example. Webinar will provide both statistical and clinical perspective.

El futuro digital de la salud

May 2021

Esta sesión describirá el potencial de las soluciones digitales para transformar la atención en salud en América Latina, los obstáculos que siguen presentes y que impiden la amplia adopción y adaptación. Exploraremos lo que podemos aprender de los ejemplos de transformación digital en América Latina y otros países.

The Power of Human+Digital Connection

May 2021

In a healthcare world saturated with digital tools – and 40% of patients turning to digital resources – the best patient outcomes actually occur when personal, human-touch plays a notable part in acclimating patients on their prescription therapy. New research suggests that adding personal connection to digital health can increase adoption by 70%, leading to greater outcomes and faster healing.

Generando inversiones para la atención en salud en América Latina

Apr 2021

Esta sesión, va a explorar modelos potenciales para generar inversiones a corto plazo para la atención en salud en América Latina, ya sea de nuevas fuentes de ingresos, opciones de financiación internacional o, inversionistas del sector privado. Incluiremos experiencias de países de América Latina así como modelos que se han mostrado prometedores en otros contextos, sectores o regiones que pueden contener lecciones aprendidas relevantes.

ISPOR's New Science Strategy - A Member-Generated Roadmap of HEOR Priorities and Frontiers

Mar 2021

This webinar will review each of the theme areas and focal points in the Strategy, the process by which they were generated, and their potential implications for future ISPOR activities.

The Impact of COVID-19 in Healthcare: Challenges and Opportunities in Latin America

Mar 2021

To help viewers better understand the region, this webinar brings together a panel of health experts across Latin America to provide multiple perspectives on the effects of COVID-19 in the healthcare of Latin America including regulatory change and innovation, public-private partnerships in health, digital transformation, regional and inter-regional cooperation and capacity building. Brought to you by ISPOR's Latin America Consortium.

Esquemas de Acuerdo Administrado/Managed Entry Agreements (MEAs)

Mar 2021

En este evento educativo, escucharemos a dos expertos que han estado a la vanguardia de los esfuerzos en America Latina por implementar estos acuerdos, con el fin de balancear el acceso a nuevas tecnologías con un financiamiento sostenible. Héctor Castro (Líder global en financiamiento a la salud, tecnologías, datos e impacto, MSH) y Alicia Ferreira (Ex-directora del Fondo Nacional de Recursos) compartirán con nosotros ejemplos reales de cómo los Acuerdos de Entrada Gestionada se están implementando progresivamente en América Latina y, recomendaciones sobre cómo crear las bases para un camino mejorado hacia un mayor acceso a tratamientos para todos los latinoamericanos.

Challenges in Assessing the Clinical and Economic Value of Future Treatments for Alzheimer’s Disease

Feb 2021

This educational webinar will describe factors that affect the assessment of the clinical and economic value of medical innovations, highlight specific issues with relevance to the societal value of treatments for AD, and place these issues in the context of future health technology assessments for AD treatments.

Reimbursement Models and Value-Assessment Approaches in the Digital Health Ecosystem – Asia Pacific Perspectives

Feb 2021

In this webinar, expert speakers will explore the current digital healthcare landscape in Asia Pacific including regulatory, value assessment and reimbursement aspects, as well as future directions. Experiences with validation, evidence generation and reimbursement pathways for digital health solutions will be also shared through case studies.

Supporting Covid19-Related Decision Making with Health Preference Research

Feb 2021

Many preference researchers have been quick to respond to this need and have conducted empirical COVID19 studies to better understand the value of health and health-related policies.

Biosimilars: Market Access Challenges & Opportunities Worldwide

Feb 2021

This webinar will present an insightful exchange on best practices, challenges and opportunities for market access of biosimilars in different regions worldwide.

Shaking the Myth of Real World Evidence: Updates From the RWE Transparency Initiative

Dec 2020

This session will provide updates from the initiative including progress on the study registration site and the special task force on RWE protocol templates.

The 4th Industrial Revolution, Digital Transformation and Patient Centricity: A Leadership View

Dec 2020

In this presentation we will explore what the 4th Industrial Revolution is, how it impacts on the progressive movement towards digital transformation in our workplace. We will show that there is an inevitable convergence between the health ecosystem and the digital world.

CHEERS II: Bold Directions for New Reporting Standards?

Dec 2020

This webinar will discuss the rationale for the revision of the original Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guidelines and outline directions for the new reporting standards, as suggested by a Delphi survey.

The Proper Order of Things is Often a Mystery: A Novel Approach to Selecting Treatment Sequences

Dec 2020

In this webinar, we will consider the apparent disconnect between HTA assessments of treatments within a specified location in a treatment sequence and clinical practice where a treatment sequence is tailored to the patient.

Long Term Value Demonstration in Alzheimer’s Disease: Evidence Needs

Dec 2020

This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.

Using Patient Preferences to Inform Decision Making

Nov 2020

The current regulatory and assessor landscape will be discussed including the European Union’s Innovative Medicines Initiative (IMI) and the Medical Device Innovation Consortium (MDIC). The task force is presenting their work to date with the request for feedback.

ISPOR/IVI COVID Webinar #5: Using VA/HTA in Pursuing Innovation and Access in a Pandemic

Nov 2020

This capstone webinar culminates the ISPOR-IVI series with a reflection on future direction and commitment needed to improve the scientific credibility and relevance of VA/HTA to pandemic preparedness.

An Introduction to Cost Analysis Methods Using Large/administrative Claims Databases

Nov 2020

Determining resource utilization patterns, treatment and disease-related costs has become an important aspect of health outcomes research to guide health care resource allocation from a payer and policy decision-making perspectives.

Value Assessment in Alzheimer's Disease: A Focus on Equity

Nov 2020

This webinar will define how Alzheimer’s disease affects underserved communities; share opportunities to create more equitable, ethical, and inclusive value frameworks; and educate on the community’s role in solving this problem.

ISPOR/IVI COVID Webinar #4: The Role of Public Health – How can VA/HTA Inform Pandemic Policy Interventions and Public Resource Allocation?

Nov 2020

COVID-19 has brought home the importance of public health expertise and investment. How should VA/HTA address risks and benefits of public health policy interventions? How do we model the interactions between health and other sectors in our economy? What are the roles of the public vs. private sector in public health infrastructure and interventions? Are there policy implications for public health investment that VA/HTA can help frame?

Patient-Reported Outcomes Webinar 2 (3 Part Series): Generating PRO Data – and Using It

Oct 2020

To advocate for a meaningful use of PROs to best reflect patient reality, patient advocates need to understand what PROs are, how PROs are being measured, and how they can bring the patient perspective into development, use and reporting of PRO measurements. This information will be presented across a 3-part webinar series

Valuing Future Alzheimer’s Disease Medicines: Extending the Paradigm

Oct 2020

This webinar seeks to explore some of these broader elements within the context of evolving value assessment and considers how they may meaningfully be incorporated to facilitate a more holistic approach to valuing medical innovation.

Patient Reported Outcomes Webinar 3: Developing New Patient-Reported Outcomes Instruments

Oct 2020

To advocate for a meaningful use of PROs to best reflect patient reality, patient advocates need to understand what PROs are, how PROs are being measured, and how they can bring the patient perspective into development, use and reporting of PRO measurements. This information will be presented across a 3-part webinar series outlined below.

Biosimilars: Unleashing The Potential For Improved Patient Access And Cost Savings In The United States

Oct 2020

The webinar will present an overview of societal benefits of biosimilars, how these are measured, how the United States (US) and select markets are tracking in attaining these benefits, and potential solutions for advancing the evidence of potential benefits into action.

ONE HEALTH Perspectives on HEOR

Oct 2020

This webinar features a range of international speakers who will introduce several One Health-related topics as they pertain to HEOR, with a view gauging interest in the formation of an ISPOR Animal and One Health Special Interest Group (SIG).

Methods Maze: Pointers for Selecting Survival Extrapolation Models for Cancer Immunotherapy

Oct 2020

In this webinar, we will be discussing this issue in relation to cancer immunotherapy. An overview of the survival extrapolation methods which could be used for cancer immunotherapies will be presented along with an assessment of their strengths and limitations. Finally, the presenters will provide attendees with some pointers to help with the selection of appropriate survival extrapolation models for these agents.

Patient-Reported Outcomes Webinar 1 (3-Part Series): Webinar 1: What are PROs and HRQOL Tools?

Sep 2020

To advocate for a meaningful use of PROs to best reflect patient reality, patient advocates need to understand what PROs are, how PROs are being measured, and how they can bring the patient perspective into development, use and reporting of PRO measurements. This information will be presented across a 3-part webinar series.

Open Source Models in HEOR: Benefits, Challenges, and ISPOR Members’ Perceptions

Sep 2020

There is growing interest in the use of open source models (OSMs) for cost-effectiveness analysis. In this session, the leaders of a new Special Interest Group (SIG) will introduce the general ISPOR membership to OSMs, providing an overview of some of the perceived benefits and potential barriers to their adoption. The presenters will share the findings of a recent survey, relaying ISPOR members’ experiences and expectations about OSMs. The webinar will be used to help shape the direction of future events and the focus of the SIG.

French Administrative Health Care Database (SNDS): Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU

Sep 2020

Certara’s extensive experience with the recently accessible French administrative healthcare database (SNDS) has provided key insights into how the database can be used for a larger impact on patient access, health technology and public health assessments

Balancing Economics and Ethics: How Can VA/HTA Support Equitable Resource Allocation?

Sep 2020

Evolving data from COVID-19 tell the story we already know: the impact of this disease affects people – especially people of color - disproportionately, both in terms of risk and prevalence, as well as access to care and outcomes. In considering VA/HTA approaches, as well as in discerning how to apply such findings, how must we address questions of ethics and equity?

COVID-19: Are Our Methods Up To The Task?

Aug 2020

The methods, assumptions, and inputs to Value Assessment (VA) and Health Technology Assessment (HTA) are an evolving debate in the US, as we seek to balance questions of population health-driven resource allocation with the unique needs of health system, employer, payer, and societal decision-making and the emerging science of patient heterogeneity and precision medicine.

Global Experiences with the Use of HTA for Health Benefit Packages Development

Aug 2020

In this session, experts from Latin America, Asia-Pacific and EMEA will discuss the role of HTA in UHC, including priority setting, coverage and financing, and share their experience in effective application of HTA to support designing benefits package for UHC while tackling the encountered challenges.

Patient Reported Outcomes in Asia Pacific: Opportunity and Challenges

Aug 2020

In this session, expert speakers from the Asia Pacific region will discuss the importance, strengths and limitations of PROs, and use case studies to illustrate how to develop valid PRO measures and how PROs support research and decision-making.

The Usage of Real-World Evidence (RWE): Monitoring and Managing Health Technologies In Latin America - Where We Are and Where We Are Heading

Aug 2020

In this webinar, a holistic multi-stakeholder discussion about the stage of RWE and how its use could improve the performance of healthcare systems in LATAM, including priority setting, health technology assessment (HTA), effectiveness and safety measurement, and innovative access models.

How Should The COVID-19 Pandemic Challenge Conventional Wisdom About HTA/VA?

Jul 2020

The initial webinar in the series will set the stage with an overview of current issues that the pandemic presents for the assessment of new technologies to prevent, treat, and potentially cure COVID-19, as well as the policy and implementation challenges.

Assessing the Impacts of a Pandemic on Pharmaceutical and Medical Device Utilization

Jul 2020

The far-reaching impacts of a pandemic on the US healthcare industry have tremendous implications for pharmaceutical and medical device utilization. Join this session to learn about the short-and long-term effects of a pandemic on healthcare utilization to inform pharmaceutical and medical device companies on how they may need to adjust their analyses of real-world data.

Patient Engagement in Research: An ISPOR Definition

Jul 2020

The purpose of this webinar is to present the ISPOR definition of “patient engagement in research.” The definition was derived from a multi-step process, including a systematic review and qualitative analysis of existing definitions, and a multi-stakeholder review.

Measurement Comparability Between Modes of Administration of PROMs-Webinar

Jul 2020

When Does Mode of Data Collection Matter? Updated and Expanded Recommendations for Collecting PRO Measures Electronically in Clinical Trials

Why and How to Use Qualitative Research Methods in Conjunction with Discrete Choice Experiments in Health Care

Jun 2020

This webinar will explore why and how to use qualitative research methods in conjunction with discrete choice experiments in healthcare. Speakers will discuss formative qualitative research for the identification and generation of attributes and levels and qualitative research for testing survey comprehension and decision-making processes.

HEOR in the Era of COVID-19

May 2020

Virtual ISPOR 2020 Preconference Plenary Session - Keynote Address: COVID-19: Accelerating the Evidence to Inform our Response Mark McClellan, MD, PhD, Director, Duke-Margolis Center for Health Policy, Washington, DC, USA Panel: COVID-19: A Global Call to Action for Health Economics & Outcomes Researchers

New Developments in Health Technology Assessment in Asia Pacific

Apr 2020

Health technology assessment (HTA) is gaining widespread acceptance and plays a vital role in healthcare decision making in many countries across the Asia Pacific region. In order to meet the changing demands of patients in light of new health technology innovations, HTA processes have needed to adapt. In this webinar, leading HTA experts from Thailand and South Korea will provide updates on recent developments in their countries’ HTA processes to strengthen patient access to innovative health technologies.

Adding Depth to Observational Research through Data Linkage

Apr 2020

This webinar will explore the value and challenges of linking administrative claims data to additional data sources in order to provide a more comprehensive look at the patient journey through a disease state. Data linkage types, techniques and best practices will be discussed.

Financing Epidemics: Developing an Insurance Scheme for Outbreaks in Africa

Apr 2020

This timely webinar will highlight an initiative under development to create an insurance scheme in African countries to provide emergency financing for disease outbreaks. Country-level engagement to tailor the scheme to country needs and costing of outbreak responses to inform estimates of premiums will be specifically addressed.

Top 10 Trends in Health Economics and Outcomes Research 2020

Apr 2020

ISPOR—the professional society for health economics and outcomes research (HEOR), announced the publication of its 2020 Top 10 HEOR Trends report early this year. In the report, the Society has identified the top 10 HEOR trends that will shape the field and influence healthcare over 2020 and the near future.

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×